NSW Poisons and Therapeutic Goods Regulation 2008 (clause 48A)
authorises appropriately trained pharmacists in NSW to administer the influenza vaccine, diphtheria-tetanus-pertussis (dTpa) vaccine, measles-mumps-rubella (MMR) vaccine and the
COVID-19 AstraZeneca (ChAdOx1-S)
vaccine to selected patients. The vaccine and conditions on the administration of the COVID-19 AstraZeneca (ChAdOx1-S) vaccine are approved by the Secretary NSW Health under
clause 48A 1A(d) and 1B of the Regulation ,
Approval for COVID-19 AstraZeneca (ChAdOx1-S) vaccine. The NSW Pharmacist Vaccination Standards and more information is available on the
NSW pharmacist vaccination program web page.
A registered pharmacist initiating and administering vaccines under his/her own authority must comply with the following three components of clause 48A of the
NSW Poisons and Therapeutic Goods Regulation 2008 which prescribes rules for:
- completing an accredited vaccination training course
- conducting vaccinations under the NSW Pharmacist Vaccination Standards
- recording each vaccination.
This provision applies to a pharmacist who holds general registration or provisional registration with the Pharmacy Board of Australia. A pharmacist with provisional registration who has completed an accredited vaccination training course may initiate and administer vaccines (other than the COVID-19 AstraZeneca (ChAdOx1-S) vaccine) only when under the supervision of a pharmacist who holds general registration, has completed an accredited vaccination training course and has determined the vaccination is appropriate for the particular person.